Metaplasia
6
0
1
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
16.7%
1 terminated out of 6 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor
Pyloric or Pseudopyloric Metaplasia of the Corpus Mucosa in Autoimmune Gastritis
Ablation of Esophageal Inlet Patches in Patients Referred for Bravo pH-Testing
Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease
Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung
Acetic Acid Chromoendoscopy to Judge Gastric Intestinal Metaplasia